Origin of Minority Drug-Resistant HIV-1 Variants in Primary HIV-1 Infection

Karin J. Metzner,1a Alexandra U. Scherrer,1,a Benjamin Preiswerk,1 Beda Joos,1 Viktor von Wyl,1 Christine Leemann,1 Philip Rieder,1 Dominique Braun,1 Christina Grube,1 Herbert Kuster,1 Jürg Böni,2 Sabine Yerly,7 Thomas Klimkait,6 Vincent Aubert,3 Hansjakob Furrer,4 Manuel Battegay,4 Pietro L. Vernazza,4 Matthias Cavassini,5 Alexandra Calmy,10 Enos Bernasconi,11 Rainer Weber,1 and Huldrych F. Günthard,1 the Swiss HIV Cohort Study2

1Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich; 2Swiss National Center for Retroviruses, University of Zurich; 3Laboratory of Virology and AIDS Center, University Hospital Geneva; 4Division of Infectious Diseases, University Hospital Geneva; 5Institute for Medical Microbiology; 6Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, University of Basel; 7Division of Immunology; 8Division of Infectious Diseases Service, University Hospital Lausanne; 9Department of Infectious Diseases, Bern University Hospital and University of Bern; 10Division of Infectious Diseases, Cantonal Hospital St Gallen; and 11Division of Infectious Diseases, Regional Hospital Lugano, Switzerland

Background. Drug-resistant human immunodeficiency virus type 1 (HIV-1) minority variants (MVs) are present in some antiretroviral therapy (ART)–naive patients. They may result from de novo mutagenesis or transmission. To date, the latter has not been proven.

Methods. MVs were quantified by allele-specific polymerase chain reaction in 204 acute or recent seroconverters from the Zurich Primary HIV Infection study and 382 ART-naive, chronically infected patients. Phylogenetic analyses identified transmission clusters.

Results. Three lines of evidence were observed in support of transmission of MVs. First, potential transmitters were identified for 12 of 16 acute or recent seroconverters harboring M184V MVs. These variants were also detected in plasma and/or peripheral blood mononuclear cells at the estimated time of transmission in 3 of 4 potential transmitters who experienced virological failure accompanied by the selection of the M184V mutation before transmission. Second, prevalence between MVs harboring the frequent mutation M184V and the particularly uncommon integrase mutation N155H differed highly significantly in acute or recent seroconverters (8.2% vs 0.5%; P < .001). Third, the prevalence of less-fit M184V MVs is significantly higher in acutely or recently than in chronically HIV-1–infected patients (8.2% vs 2.5%; P = .004).

Conclusions. Drug-resistant HIV-1 MVs can be transmitted. To what extent the origin—transmission vs sporadic appearance—of these variants determines their impact on ART needs to be further explored.

Keywords. HIV-1; primary HIV-1 infection; drug resistance; transmission; drug-resistant HIV-1 minority variants; prevalence; allele-specific real-time PCR.

Drug resistance testing is recommended before first-line antiretroviral therapy (ART) [1]. Routine genotypic resistance testing is based on population sequencing, thus, missing minority variants (MVs) at levels <20%–25% of the virus population [2, 3]. Although the impact of drug-resistant human immunodeficiency virus type 1 (HIV-1) MVs on the success of ART is still debated [4], a substantial number of ART-naive patients harbor such variants, which can lead to rapid selection of drug-resistant viruses and subsequent treatment failure especially in the context of regimens with a low genetic barrier to resistance [5–7].

Drug-resistant HIV-1 MVs can be frequently detected in acutely or recently HIV-1–infected patients [8–13]. They may appear due to de novo mutagenesis [14] or result from transmission, as assumed by others and our group [11, 12, 15, 16]. Transmission of MVs, however, has not been proven so far.
In this study we analyzed large data sets of drug-resistant HIV-1 MVs in acutely or recently and chronically HIV-1-infected patients, compared their frequencies in and within both groups, and performed phylogenetic transmission cluster analyses providing several lines of evidence that transmission of MVs occurs.

METHODS

Patients and Study Design
Between March 2002 and February 2011, plasma samples from 204 patients from the Zurich Primary HIV Infection (ZPHI) cohort were obtained from ethylenediaminetetraacetic acid-treated blood samples collected at the earliest available time point during acute or recent infection and before initiation of ART. The ZPHI study is an observational, open label, nonrandomized, single center study (www.clinicaltrials.gov; ID NCT00537966) [9, 17, 18]. Acute and recent HIV-1 infection were defined as described in detail elsewhere [18]. In addition, 382 samples from treatment-naive, chronically infected patients from the Swiss HIV Cohort Study (SHCS) were analyzed. Plasma samples were collected between October 1994 and June 2008. The SHCS has been approved by ethical committees from all participating institutions, and written informed consent has been obtained from all individuals [19]. Peripheral blood mononuclear cells (PBMCs) were obtained from potential transmitter-recipient pairs.

Viral Load and Resistance Testing
The plasma HIV-1 viral load was quantified using the Cobas AmpliPrep/Cobas TaqMan HIV-1 Test, versions 1 and 2.0 (Roche Diagnostics) with detection limits of 40 and 20 HIV-1 RNA copies/mL plasma, respectively. Genotypic resistance testing was performed by population sequencing (ViroSeq version 1 [PE Biosystems]; ViroSeq version 2 [Abbott], and vircoTYPE HIV-1 Assay [Virco Laboratory]) and in-house methods [20]. Drug resistance mutations were defined as recommended by the International Antiviral Society–USA Drug Resistance Mutations Group and the surveillance drug resistance mutations list [21, 22]. Proviral DNA copy numbers were determined by quantitative polymerase chain reaction (PCR) amplification of part of the HIV-1 gag gene and the single copy gene CCR5 (CC chemokine receptor 5) and then calculated per 10^6 genomic equivalents.

Allele-Specific Real-Time PCR for Quantification of K103N, Y181C, M184V, and N155H Drug-Resistant HIV-1 MVs
Viral RNA and DNA from 0.5–1 mL plasma and PBMCs, respectively, were analyzed by allele-specific PCR (AS-PCR) quantifying MVs. The AS-PCR assays for the K103N, Y181C, and M184V mutations have been described elsewhere [7, 10, 23], and the N155H AS-PCR is described in the Supplementary data. The PCR conditions, amplicon purification, and data analysis are described elsewhere [9, 10, 23], and the K103N AS-PCR has been further validated in a blinded, multicenter comparison of sensitive methods for detecting MVs [24]. Each AS-PCR has a dynamic range of 6 logs and a detection limit of 10 HIV-1 DNA copies per reaction. The discriminatory abilities were 0.01% for the K103N-, 0.2% for the Y181C- and M184V-, and 0.3% for the N155H mutation. However, to compare the prevalences of those MVs in different patient groups, we chose a similar cutoff of 0.3% for all MVs. A detailed description of the establishment and validation of the AS-PCR assays, including their discriminatory abilities and the calculation of the limit of detection in samples with viral loads <8334 HIV-1 RNA copies/mL (ie, not reaching the cutoff of 0.3%) are given in Supplementary Figures 1 and 2 and Supplementary Table 1.

C2-V3-C3 Loop Sequencing
Clonal sequencing of C2-V3-C3 env fragments was performed as described elsewhere [18], and population sequencing of C2-V3-C3 env fragments was performed using the same conditions.

Phylogenetic Analyses
All available HIV-1 pol sequences (in total 18 586 sequences obtained from the SHCS drug resistance database [25]) were aligned using the profile HMM method (hmmlalign, HMMER version 3.0; http://hmmer.janelia.org [26]) and used to calculate a distance matrix with DNADIST software employing the F84 model with a transition-transversion ratio of 2.0 (PHYLIP Phylogeny Inference Package version 3.69; distributed by J. Felsenstein, Department of Genetics, University of Washington, Seattle). A total of 2206 sequences were selected, based on their genetic distance <1.5% from any of the ZPHI sequences, and used to search for potential transmission clusters. Neighbor joining phylogenetic trees were inferred by the MEGA4 Tamura Nei 6-parameter model [27] and bootstrapping (1000 replications), and HIV-1 HXB2 was used as the reference strain.

Statistical Analyses
Prevalences of mutations were compared with Fisher exact test, and the Mann–Whitney U test was used for group comparison; both tests were performed with Stata 11 SE software (StataCorp). All P values are 2 sided, and the level of significance was set at P <.05.

RESULTS

Patient Characteristics
From January 2002 through February 2011, a total of 265 patients were included in the ZPHI cohort. Genotypic resistance testing was performed by population sequencing before ART in all but 1 patient. Of the 3 RT drug resistance mutations tested with AS-PCR, the Y181C and M184V mutations were not detected in any patients, and the K103N mutation was detected in
2, who were excluded from the K103N MV analysis. Drug-resistant HIV-1 MVs were retrospectively quantified by AS-PCR in 204 patients, of whom 181 were infected with HIV-1 subtype B (88.7%). Sixty-one of the 265 patients were not included for the following reasons: too many mismatches in the primer binding sites of the AS-PCR assays (31 patients; HIV-1 non-B subtype), no plasma sample available (14 patients), dropping out of the study (7 patients), inability to confirm acute or recent HIV-1 infection at the time of study entry (8 patients), and undetectable viral load in 1 elite controller. The AS-PCR assays failed repeatedly in 10 (K103N), 25 (Y181C), 8 (M184V), and 11 (N155H) of 204 patients for unexplained reasons. The M184V AS-PCR assay was not applicable in 1 patient owing to too many primer mismatches. Baseline samples were available for the M184V and K103N determinations for all patients (n = 204) but not anymore for 26 patients (Y181C) and 8 patients (N155H).

Chronically HIV-1–infected patients were included from the SHCS when they fulfilled the following criteria: (1) chronic HIV-1 infection, as defined by the presence of a first positive HIV test ≥6 months before sampling; (2) plasma sample available before first ART with a viral load of >1000 HIV-1 RNA copies/mL; (3) no detection of K103N, Y181C, or M184V/I mutation by routine genotypic resistance testing before first ART (in 2 patients, the K103N mutation was retrospectively detected as the major virus population in the plasma sample used for AS-PCR, and these patients were excluded from the K103N MV analysis). Plasma samples from 382 patients were analyzed with AS-PCR; 93.7% of those patients were infected with HIV-1 subtype B. The AS-PCR assays failed repeatedly in 47 (K103N), 10 (Y181C), 15 (M184V), and 23 (N155H) patients for unexplained reasons. The AS-PCR assays were not applicable in 9 (K103N), 4 (Y181C), and 4 (M1184V) patients because of too many primer mismatches. Baseline samples were available for the M184V and K103N determinations for all patients (n = 382) but not anymore for 33 patients (Y181V) or 213 patients (N155H).

Transmission Clusters and Possible Transmission of Drug-Resistant MVs

Transmission clusters were discovered by phylogenetic analysis of 446 HIV-1 pol sequences from 262 ZPHI patients together with 1760 related sequences, which were selected by screening the entire SHCS drug resistance database containing all routine genotypic resistance testing by population sequencing [25]. Sixteen ZPHI patients harbored M184V MVs, and 12 patients could be localized in clusters together with potential transmitters. These were further explored, and in 4 clusters the most likely transmitters had a history of virological failure and selection of M184V viruses before presumed transmission. All 4 recipients were classified as acutely HIV-1 infected (Fiebig stages IV, IV, V/VI, and VI [28]; estimated time of infection, ≤90 days).

Table 1. M184V-Harboring HIV-1 MVs in Plasma and PBMCs From Pairs of Recipients and Potential Transmitters

<table>
<thead>
<tr>
<th>Patient ID</th>
<th>Time Pointa (Stage)</th>
<th>M184V MV in Plasma</th>
<th>M184V MV in PBMCs</th>
<th>Proviral Load DNA, Copies/10⁶ GE</th>
</tr>
</thead>
<tbody>
<tr>
<td>1A (likely transmitter)</td>
<td>1 (virological failure)</td>
<td>. . .</td>
<td>. . .</td>
<td>28.4 ± 0.8</td>
</tr>
<tr>
<td>2 (approx 8.4 wk after ETT)</td>
<td>2 (approx 8.4 wk after ETT)</td>
<td>&lt;0.3</td>
<td>&lt;1641</td>
<td>547 000</td>
</tr>
<tr>
<td>ZPHI 1</td>
<td>3 (approx 8.6 wk after ETT; Fiebig stage V/VI)</td>
<td>0.4 ± 0.0</td>
<td>349</td>
<td>87 300</td>
</tr>
<tr>
<td>2A (likely transmitter)</td>
<td>4 (virological failure)</td>
<td>. . .</td>
<td>. . .</td>
<td>34.4 ± 1.7</td>
</tr>
<tr>
<td>5 (approx 7.4 wk after ETT)</td>
<td>5 (approx 7.4 wk after ETT)</td>
<td>0.4 ± 0.0</td>
<td>676</td>
<td>169 000</td>
</tr>
<tr>
<td>ZPHI 2</td>
<td>6 (approx 8 wk after ETT; Fiebig stage IV)</td>
<td>0.4 ± 0.0</td>
<td>204</td>
<td>51 100</td>
</tr>
<tr>
<td>3A (likely transmitter)</td>
<td>7 (virological failure)</td>
<td>. . .</td>
<td>. . .</td>
<td>&lt;4.3</td>
</tr>
<tr>
<td>8 (approx 14.4 wk before ETT)</td>
<td>8 (approx 14.4 wk before ETT)</td>
<td>&lt;0.3</td>
<td>&lt;648</td>
<td>216 000</td>
</tr>
<tr>
<td>9 (approx 11.6 wk after ETT)</td>
<td>9 (approx 11.6 wk after ETT)</td>
<td>&lt;0.3</td>
<td>&lt;648</td>
<td>216 000</td>
</tr>
<tr>
<td>ZPHI 3</td>
<td>10 (approx 3.6 wk after ETT; Fiebig stage IV)</td>
<td>0.4 ± 0.1</td>
<td>3720</td>
<td>930 000</td>
</tr>
<tr>
<td>11 (virological failure)</td>
<td>11 (virological failure)</td>
<td>. . .</td>
<td>. . .</td>
<td>93.6 ± 0.5</td>
</tr>
<tr>
<td>12 (approx 14.4 wk before ETT)</td>
<td>12 (approx 14.4 wk before ETT)</td>
<td>&lt;0.3</td>
<td>&lt;780</td>
<td>260 000</td>
</tr>
<tr>
<td>ZPHI 4</td>
<td>13 (approx 11 wk after ETT; Fiebig stage VI)</td>
<td>0.7 ± 0.1</td>
<td>3290</td>
<td>470 000</td>
</tr>
</tbody>
</table>

Abbreviations: approx, approximately; ellipses (…), not performed; ETT, estimated time of transmission; GE, genomic equivalents; HIV-1, human immunodeficiency virus type 1; MV, minority variant; PBMCs, peripheral blood mononuclear cells; ZPHI, Zurich Primary HIV Infection study.

a Time points 1–13 as indicated in Figure 2.
before sampling; Table 1). Individual subtrees clipped from the neighbor joining tree, including a total of 2206 sequences, show the phylogenetic analysis of HIV-1 pol sequences of those 4 clusters (Figure 1A). The likely transmitters were confirmed by phylogenetic analysis of their HIV-1 env C2-V3-C3 sequences combined with clonal sequences isolated from the recipients (Figure 1B).

Other criteria were also used to define the most likely transmitters. None of the potential transmitters were receiving treatment at the estimated time of transmission (Figure 2), and all potential transmitters had a high viral load at the time of transmission (Figure 2). Potential transmitter-recipient pairs belonged to the same risk group (men who have sex with men) and originated from the same geographic regions.

In the following analysis, we focused on the 4 clusters that included most likely transmitters with a history of virological failure and the potential to transmit preselected drug-resistant variants as MVs. All 4 potential transmitters experienced ART failure and selected the M184V mutation as major virus population 0.5 to 9.4 years before transmission (Figure 2). By population sequencing, the M184V mutation was not detectable any more during the time window of likely transmission (Figure 2); AS-PCR was then performed on plasma samples as close as possible to the time of transmission. The M184V mutation was detected in 1 potential transmitter at similar levels as in the recipient (0.4%; Table 1). In the remaining 3 potential transmitters, the M184V mutation was not detectable (<0.3%) in the plasma virus population at the estimated time point of transmission.

Next, proviral DNA was analyzed by AS-PCR to investigate the presence of the M184V mutation in the PBMC compartment, which can retain previously replicating variants. Notably, PBMCs from 3 of the 4 potential transmitters harbored the M184V mutation as MVs in frequencies of 1.9%–4.2% (Table 1). The M184V mutation was not present in proviral
DNA from the potential transmitter 1A or in any of the 4 recipients at the estimated time point of transmission (Table 1).

**M184V vs N155H Mutations as MVs in Acutely or Recently HIV-1 Infected Patients**

The M184V mutation was detected as a MV in 16 of 195 acutely or recently HIV-1–infected patients (8.2%), Y181C was detected in 4 of 153 (2.6%), K103N in 4 of 192 (2.1%), and N155H in 1 of 185 (0.5%) (Figure 3A), at frequencies of 0.4%–8.3%, 0.5%–0.7%, 0.83%–3.76%, and 0.9% (Figure 4A), respectively. The difference between the very commonly detected mutation M184V and the particularly uncommon integrase mutation N155H was significant (P < .001). This was also the case when the analysis was restricted to only patients who were infected with HIV-1 subtype B and belonged to the risk group of men who have sex with men (P < .001; Figure 3B). Both groups of acutely or recently HIV-1–infected patients—those harboring and not harboring drug-resistant HIV-1 MVs—showed no differences in CD4+ T cell count, viral load, HIV-1 subtype, sex, risk group, Fiebig staging, or time between estimated time of infection and sampling (Table 2).

**M184V Mutation in Acutely or Recently vs Chronically HIV-1 Infected Patients**

The detection of MVs containing the K103N, Y181C, M184V, or N155H mutation was compared in 204 acutely or recently

Figure 2. Time course analysis of potential transmission pairs. Viral load kinetics of the potential transmitter (blue circles) and the recipient (red circles) are presented over time, and the estimated time of transmission is indicated (gray shaded area). Treatment history of the potential transmitter (black and green lines) represents antiretroviral therapy without or with lamivudine or emtricitabine, respectively, as well as the first-line antiretroviral therapy of the recipient (red lines). Genotypic resistance testing by population sequencing was performed at several time points before and during the time of transmission in the potential transmitter (black arrows); the results regarding codon 184 of the reverse transcriptase (RT) are labeled M and V for M184 and M184V, respectively. Minority M184V–comprising human immunodeficiency virus type 1 (HIV-1) variants were assessed by allele-specific polymerase chain reaction in plasma and peripheral blood mononuclear cells at the indicated time points 1–13. These results are provided in Table 1. Abbreviations: 3TC, lamivudine; ABC, abacavir; ATV, atazanavir; ATV/r, ritonavir-boosted ATV; AZT, zidovudine; d4T, stavudine; dC, zalcitabine; dL, didanosine; DRV/r, ritonavir-boosted darunavir; EFV, efavirenz; FPV/r, ritonavir-boosted fosamprenavir; FTC, emtricitabine; IDV, indinavir; LPV, lopinavir; LPV/r, ritonavir-boosted LPV; SQV, saquinavir; TNV, tenofovir.
and 382 ART-naive, chronically HIV-1–infected patients. The latter group harbored drug-resistant HIV-1 MVs before first ART as follows: K103N in 10 of 324 patients (3.1%) at frequencies of 0.76%–22.14%, Y181C in 16 of 325 (4.9%) at frequencies of 0.5%–13.7%, M184V in 9 of 363 (2.5%) at frequencies of 0.9%–3.2%, and N155H in none of 146 patients (Figure 3A and Figure 4B).

In 16 of 195 acutely or recently HIV-1–infected patients (8.2%), M184V MVs were present, compared with 9 of 363 chronically HIV-1–infected patients (2.5%), a significant difference ($P = .004$; Figure 3A). The K103N and Y181C mutations were similarly present in both patient groups (2.1% vs 3.1% and 2.6% vs 4.9%, respectively; $P > .05$). The N155H integrase mutation was not detected in chronically HIV-1–infected patients (Figure 3A).

As expected, the 2 groups—acutely or recently and chronically HIV-1–infected patients—differed significantly in terms of CD4$^+$ T cell count, which was lower in chronically infected patients, and viral load, which was higher in acutely or recently infected patients (Table 2). They also differed significantly with regard to the interdependent parameters of sex, risk group, and HIV-1 subtype (Table 2). This shows that the chosen group of chronically infected patients well represents ART-naive patients within the nationwide Swiss HIV Cohort Study [29]. To exclude any bias derived from these parameters, only men who have sex with men and infected with HIV-1 subtype B were included in a sensitivity analysis. Again, the numbers of patients harboring the M184V mutation as MVs differed significantly between acutely or recently and chronically HIV-1–infected patients ($P = .03$; Figure 3B).

As shown for those infected acutely or recently, chronically HIV-1–infected patients harboring or not harboring drug-resistant HIV-1 MVs showed no significant differences in the parameters CD4$^+$ T cell count, viral load, HIV-1 subtype, sex, risk group, Fiebig staging, and time between estimated time of infection and sampling (Table 2). Notably, the percentages of patients with a viral load $\geq 8334$ HIV-1 RNA copies/mL plasma were similar in all groups (Table 2); that is, drug-resistant HIV-1 MVs can be detected in those patients to the defined cutoff of 0.3% without any restrictions due to too low viral loads. Thus, a higher rate of false-negative results can be excluded in chronically infected patients despite the lower median of the viral loads.

**DISCUSSION**

This study provides several lines of strong evidence that transmission of drug-resistant HIV-1 MVs can occur, a phenomenon often assumed but not proved so far. First, potential transmitters of 4 transmitter-recipient pairs experienced ART failure and selected the M184V mutation 0.5 to 9.4 years before transmission. During the time of transmission, the M184V mutation was no longer detected in plasma by population sequencing, but in 1 of those potential transmitters it was present as a MV in the plasma virus population. In 3 potential transmitters, M184V-harboring HIV-1 MVs were detected at frequencies of up to 4.2% in PBMCs. This compartment contains ancestral viral strains that are more likely to be transmitted than contemporary viral variants [30]. Thus, the PBMC compartment
Figure 4. Detection of drug-resistant human immunodeficiency virus type 1 (HIV-1) minority variants (MVs) in plasma and peripheral blood mononuclear cells (PBMCs) from acutely or recently and chronically HIV-1–infected patients and reproducibility/accuracy of the allele-specific polymerase chain reaction (AS-PCR) assays for K103N, Y181C, M184V, and N155H. The K103N, Y181C, M184V, and N155H drug resistance mutations were measured with AS-PCR in plasma of acutely or recently (A) and chronically (B) HIV-1–infected patients, as was the M184V mutation in PBMCs from the 4 potential transmitter-recipient pairs (C). The values of the samples below the detection limit (dotted line, 0.3%) are represented as gray dots. The open circles represent samples with values >0.3% but for which the corresponding viral load is too low to verify the presence of drug-resistant HIV-1 variants. Black dots represent the samples that contained drug-resistant HIV-1 MVs. D. Each sample processing and AS-PCR run included 13 plasma samples from patients and a wild-type as well as a 1% mutant virus control. The wild-type control contained virus particles from a HIV-1NL4-3 virus stock with a virus titer of 10,000 RNA copies in 1 mL of plasma from an HIV-1 negative donor. The 1% mutant control was a mixture of HIV-1NL4-3 virus stock (9900 RNA copies) and the respective mutant virus stock HIV-1NL4-3_K103N, HIV-1NL4-3_Y181C, HIV-1NL4-3_M184V, and HIV-1NL4-3_N155H (100 RNA copies) in 1 mL of plasma from an HIV-1 negative donor. Data represent results of 28–78 independent experiments in which each sample was assayed in duplicate; median and interquartile ranges are given. Abbreviation: dl, detection limit.
Table 2. Demographic Data and Clinical Baseline Parameters in Acutely or Recently and Chronically, ART-Naive HIV-1–Infected Patients Harboring or Not Harboring Drug-Resistant HIV-1 MVs

<table>
<thead>
<tr>
<th>Data</th>
<th>Acutely or Recently HIV-1–Infected Patients (n = 204)</th>
<th>Chronically HIV-1–Infected Patients (n = 382)</th>
<th>Acutely or Recently HIV-1–Infected Patients Not Harboring MVs (n = 181)</th>
<th>Acutely or Recently HIV-1–Infected Patients Harboring MVs (n = 23)</th>
<th>P Value</th>
<th>Chronically HIV-1–Infected Patients Not Harboring MVs (n = 352)</th>
<th>Chronically HIV-1–Infected Patients Harboring MVs (n = 30)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, median (range), y</td>
<td>34 (18–70)</td>
<td>38 (22–71)</td>
<td>&lt;.001&lt;sup&gt;a&lt;/sup&gt;</td>
<td>34 (18–70)</td>
<td>40 (23–64)</td>
<td>.02&lt;sup&gt;a&lt;/sup&gt;</td>
<td>38 (22–71)</td>
<td>37 (23–57)</td>
</tr>
<tr>
<td>CD4&lt;sup&gt;+&lt;/sup&gt; T cell count, median (range), cells/µL blood</td>
<td>399 (87–1304)</td>
<td>232 (0–800)</td>
<td>&lt;.001&lt;sup&gt;a&lt;/sup&gt;</td>
<td>397 (87–1304)</td>
<td>423 (150–1041)</td>
<td>NS&lt;sup&gt;a&lt;/sup&gt;</td>
<td>232 (0–800)</td>
<td>212 (0–740)</td>
</tr>
<tr>
<td>HIV-1 RNA load, median (range), log&lt;sub&gt;10&lt;/sub&gt; copies/mL plasma</td>
<td>5.3 (2.7–8.0)</td>
<td>4.9 (3.0–7.0)</td>
<td>&lt;.001&lt;sup&gt;a&lt;/sup&gt;</td>
<td>5.3 (2.7–8.0)</td>
<td>5.6 (3.2–7.5)</td>
<td>NS&lt;sup&gt;a&lt;/sup&gt;</td>
<td>4.9 (3.0–7.0)</td>
<td>4.6 (3.8–6.9)</td>
</tr>
<tr>
<td>Patients, No. (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VL ≥8334 copies/mL plasma&lt;sup&gt;b&lt;/sup&gt;</td>
<td>188 (92.2)</td>
<td>345 (90.3)</td>
<td>NS&lt;sup&gt;c&lt;/sup&gt;</td>
<td>168 (92.8)</td>
<td>20 (87.0)</td>
<td>NS&lt;sup&gt;c&lt;/sup&gt;</td>
<td>316 (89.8)</td>
<td>29 (96.7)</td>
</tr>
<tr>
<td>VL &lt;8334 copies/mL plasma&lt;sup&gt;d&lt;/sup&gt;</td>
<td>16 (7.8)</td>
<td>37 (9.7)</td>
<td>.04&lt;sup&gt;c&lt;/sup&gt;</td>
<td>13 (7.2)</td>
<td>3 (13.0)</td>
<td>36 (10.2)</td>
<td>1 (3.3)</td>
<td></td>
</tr>
<tr>
<td>HIV-1 subtype B</td>
<td>181 (88.7)</td>
<td>358 (93.7)</td>
<td>.04&lt;sup&gt;c&lt;/sup&gt;</td>
<td>158 (87.3)</td>
<td>23 (100)</td>
<td>NS&lt;sup&gt;c&lt;/sup&gt;</td>
<td>328 (93.2)</td>
<td>30 (100)</td>
</tr>
<tr>
<td>HIV-1 subtype non-B</td>
<td>23 (11.3)</td>
<td>24 (6.3)</td>
<td></td>
<td>23 (12.7)</td>
<td>0</td>
<td>24 (6.8)</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>194 (95.1)</td>
<td>301 (78.8)</td>
<td>&lt;.001&lt;sup&gt;c&lt;/sup&gt;</td>
<td>172 (95.0)</td>
<td>22 (95.6)</td>
<td>NS&lt;sup&gt;c&lt;/sup&gt;</td>
<td>274 (77.8)</td>
<td>27 (90.0)</td>
</tr>
<tr>
<td>Female</td>
<td>10 (4.9)</td>
<td>81 (21.2)</td>
<td></td>
<td>9 (5.0)</td>
<td>1 (4.4)</td>
<td>78 (22.2)</td>
<td>3 (10.0)</td>
<td></td>
</tr>
<tr>
<td>MSM</td>
<td>167 (81.9)</td>
<td>197 (51.6)</td>
<td>&lt;.001&lt;sup&gt;c,e&lt;/sup&gt;</td>
<td>147 (81.2)</td>
<td>20 (87.0)</td>
<td>NS&lt;sup&gt;c&lt;/sup&gt;</td>
<td>178 (50.6)</td>
<td>19 (63.3)</td>
</tr>
<tr>
<td>Heterosexual</td>
<td>33 (16.2)</td>
<td>118 (30.9)</td>
<td>.04&lt;sup&gt;c&lt;/sup&gt;</td>
<td>30 (16.6)</td>
<td>3 (13.0)</td>
<td>113 (32.1)</td>
<td>5 (16.7)</td>
<td></td>
</tr>
<tr>
<td>IDU</td>
<td>1 (0.5)</td>
<td>56 (14.7)</td>
<td></td>
<td>1 (0.6)</td>
<td>0</td>
<td>50 (14.2)</td>
<td>6 (20.0)</td>
<td></td>
</tr>
<tr>
<td>IDU or heterosexual</td>
<td>2 (1.0)</td>
<td>11 (2.9)</td>
<td></td>
<td>2 (1.1)</td>
<td>0</td>
<td>11 (3.1)</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Needle stick</td>
<td>1 (0.5)</td>
<td>0</td>
<td></td>
<td>1 (0.6)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Fiebig stage</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I-IV</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>V-VI</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acute infection (≤90 d after ETI)&lt;sup&gt;g&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Recent infection (&gt;90 to ≤180 d after ETI)&lt;sup&gt;g&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time of sampling after ETI, median (range), wk</td>
<td>6.3 (2.1–26.6)</td>
<td>6.0 (1.7–18.1)</td>
<td>NS&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: ART, antiretroviral therapy; ETI, estimated time of infection; heterosexual, heterosexual transmission; HIV-1, human immunodeficiency virus type 1; IDU, injection drug use; MSM, men who have sex with men; MVs, minority variants; NS, not significant; VL, viral load.

<sup>a</sup> Mann-Whitney U test.

<sup>b</sup> For the detection of MVs to levels down to 0.3%, the viral load has to be ≥8334 HIV-1 RNA copies/mL plasma.

<sup>c</sup> Fisher exact test.

<sup>d</sup> In samples with a viral load <8334 HIV-1 RNA copies/mL plasma, the cutoff for allele-specific polymerase chain reaction has to be individually calculated.

<sup>e</sup> MSM vs non-MSM.

<sup>f</sup> Fiebig stage I–IV vs V–VI.

<sup>g</sup> Estimated as described elsewhere [17].
likely possibility is that with the previously chosen cloning approach the resolution may have been too low to detect minority species. We postulate that >1 virus is transmitted and that each virus within the viral quasispecies has a certain probability of being transmitted. As a theoretical example, assume that a recipient is exposed to 1000 viruses, of which 10 cross the mucosal barrier, and assume that 2% of the viruses carry a drug-resistance mutation. Then the probability is 16.8% that 1 of those 10 transmitted viruses contain a drug-resistance mutation, given that transmission is a stochastic process. One of those viruses, or sometimes more, generates the founder virus population. Because drug resistance mutations are often associated with a decrease of viral fitness, it is unlikely that the drug-resistant virus variant will be the founder virus. However, it is assumable that the transmitted drug-resistant HIV-1 MV replicates at very low frequencies, as seen in our 4 recipients. In previous longitudinal analyses of viral populations in chronically HIV-1–infected patients, we have shown that drug-resistant HIV-1 viruses can replicate at low levels in the absence of ART and within a major virus population of drug-sensitive viruses [16, 23]. Although we could just include 4 transmission-recipient pairs, we were able to analyze plasma and cell samples from both the potential transmitters and the recipients very close to the estimated time point of transmission. In 1 case report, a mother-to-child-transmission of a drug-resistant HIV-1 MV is assumed [15], but uncertainty remains because the analyzed child’s and mother’s samples were taken approximately 3 and 6.5 years, respectively, after the estimated time of transmission.

Second, the prevalence of drug-resistant HIV-1 MVs in acutely or recently HIV-1–infected patients mirrors the prevalence of those mutations in ART-experienced patients, a group of potential transmitters [34], and acute seroconverters in Switzerland [35] as monitored by population sequencing. The very common mutation M184V was the most frequently detected drug resistance mutation, followed by the NNRTI mutations Y181C and K103N. The so-far particularly uncommon integrase mutation N155H was almost absent in acutely or recently HIV-1–infected patients. Of note, during the investigated time period, selection pressure on integrase was virtually absent in the Swiss HIV-1–infected population because the first integrase inhibitor was approved for salvage therapy only in 2008 [36]. Thus, any detection of the N155H mutation might reflect the level of de novo mutagenesis. Note that biases due to different assay sensitivities can be excluded because the same cutoff was chosen for all AS-PCR assays.

If sporadic appearance alone was the reason for the emergence of drug-resistant HIV-1 MVs in ART-naive, acutely or recently HIV-1–infected patients, a more similar distribution of these mutations would be expected, provided that transitions occur 2–3-fold more often than transversions, especially during the early phase of infection [37]. The M184V and Y181C mutations are transitions, and the K103N and N155H mutations are transversions. However, the observed 16-fold difference in the prevalences of N155H and M184V mutations as MVs cannot be explained by preferential transitions. In addition, a higher rate of Y181C mutation and a lower rate of K103N mutation would have been expected. Thus, sporadic appearance alone cannot explain the observed pattern in the prevalence of drug-resistant HIV-1 MVs in acutely or recently HIV-1–infected patients.

HIV-1 RNA structure and other sequence characteristics could potentially favor the sporadic appearance of certain mutations as it was shown for the K65R mutation in HIV-1 subtype C [38]. However, to our knowledge this has not yet been described for the M184V mutation. In addition, this potential explanation is not in concordance with our observation that the prevalence of the M184V mutation is significantly lower in chronically than in acutely or recently HIV-1–infected patients.

Hypothetically, ineffective pre- and/or postexposure prophylaxis could explain the higher prevalence of the M184V mutation compared to the N155H mutation, because most of the prophylaxis regimens contain either 3TC or FTC but not an integrase inhibitor; thus, a failing prophylaxis would lead to the selection of the M184V mutation. The use of preexposure prophylaxis can be excluded in our patient cohort, because almost all patients were included before its success was reported at the end of 2010 [39], and it has not yet been introduced in Switzerland. Postexposure prophylaxis can also be ruled out in our patients. So far, only 2 of the 204 patients were undergoing postexposure prophylaxis during the time of transmission, as verified by systematic interviews. In both patients, drug-resistant HIV-1 MVs were not detected.

Third, the prevalence of drug-resistant HIV-1 MVs in chronically HIV-1–infected patients and the comparison with acutely or recently HIV-1–infected patients reflect exactly what is expected to follow after transmission of such MV drug-resistant viruses. The minor population harboring the M184V mutation vanishes over time due to its lower replicative capacity [40], and the K103N and Y181C mutations remain unchanged owing to their negligible impact on viral fitness [41].

In summary, sporadic appearance of drug-resistant HIV-1 MV might occur, but our observations cannot be explained solely by de novo mutagenesis. Thus, we show for the first time that drug-resistant HIV-1 MVs can be transmitted. The origin of drug-resistant HIV-1 MVs may have clinical implications, because it is conceivable that transmitted MVs might be able to establish a pool of latently infected cells more easily and profoundly than sporadically appearing MVs and that transmitted MVs might not tend to disappear as readily as sporadically appearing ones. The latter phenomenon has been observed in 1 of our ZPHI patients, who harbored the K103N mutation as a MV during primary HIV-1 infection, a variant that reappeared and persisted during treatment interruption of early ART [16].
Thus, the origin of drug-resistant HIV-1 MVs might help to explain the observed and still puzzling different clinical outcomes in ART-naive patients harboring those MVs and beginning ART.

**Supplementary Data**

Supplementary materials are available at The Journal of Infectious Diseases online (http://jid.oxfordjournals.org/). Supplementary materials consist of data provided by the author that are published to benefit the reader. The posted materials are not copyrighted. The contents of all supplementary data are the sole responsibility of the authors. Questions or messages regarding errors should be addressed to the author.

**Notes**


**Financial support.** This work has been supported in the framework of the SHCS, supported by the Swiss National Science Foundation (grant 33CS30_114277) and the SHCS research foundation. Further support was provided by the Swiss National Science Foundation (grants 324700–120793 to H. F. G. and K. J. M. and 320000–116035 and 324730–130865 to H. F. G.), the SHCS (project 605; to H. F. G. and K. J. M.), the University of Zurich’s Clinical Research Priority Program “Viral Infectious Diseases: Zurich Primary HIV Infection Study” (to H. F. G.), the European Community’s Seventh Framework Programme (grant FP7/2007–2013), under the Collaborative HIV and Anti-HIV Drug Resistance Network (CHAIN) (grant 22311310 H. F. G.); an unrestricted research grant from the Vontobel Stiftung (to H. F. G. and K. J. M.); and one from Glideo (to H. F. G.).

**Potential Conflict of Interest.** K. J. M. received travel grants and honoraria from Gilead Sciences, Roche Diagnostics, Tibotec, Bristol-Myers Squibb, and Abbott; the University of Zurich has received research grants from Gilead, Roche, and Merck Sharp & Dohme for studies for which K. J. M. serves as principal investigator and advisory board honoraria from Gilead Sciences. B. P. has received a travel grant from Roche. S. Y. has been an advisor and/or consultant for Bristol-Myers Squibb and has received travel grants and honoraria from Gilead Sciences, ViIV, and Merck Sharp & Dohme. T. K. served as advisor for Bristol-Myers Squibb and Pfizer and has received travel grants from Abbott and Pfizer. The institution of H. F. G. has received payments for participation in advisory boards and/or unrestricted educational grants and/or travel grants from Abbott, Bristol-Myers Squibb, ViIV Healthcare, Roche, Gilead, Merck Sharp & Dohme, Boehringer-Ingelheim, and Tibotec-Janssen and unrestricted research support from Gilead, Merck Sharp & Dohme, and Roche. M. B has been an advisor for Janssen-Tibotec and has received educational and research grants from Boehringer-Ingelheim, Bristol-Myers Squibb, Abbott, Janssen-Tibotec, ViIV Healthcare, Gilead, and Merck Sharp & Dohme. P. L. V. and his institution have received travel grants and speaker fees or advisory board honoraria from Abbott, Bristol-Myers Squibb, Gilead, Janssen, Merck Sharp & Dohme, Roche, and ViIV Healthcare. M. C. received unrestricted research grant from Gilead and Merck Sharp & Dohme and received travel grants from Boehringer-Ingelheim, Bristol-Myers Squibb, Gilead, and Merck Sharp & Dohme; his institution received advisory board honorarium from Bristol-Myers Squibb, Gilead, Merck Sharp & Dohme, Janssen-Cilag and Viiv. A. C. has received research grants from Abbott, Janssen-Cilag, and Gilead and travel grants from Janssen Cilag, and Gilead. R. W. has received travel grants from Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Merck Sharp & Dome, Pfizer, Roche, TRB Chemedica, and Tibotec. H. F. G. has been an adviser and/or consultant for GlaxoSmithKline, Abbott, Gilead, Novartis, Boehringer Ingelheim, Roche, Tibotec, Pfizer and Bristol-Myers Squibb, and has received unrestricted research and educational grants from Roche, Abbott, Bristol-Myers Squibb, Gilead, Astra-Zeneca, GlaxoSmithKline, and Merck Sharp & Dohme (all money went to the institution). All other authors declare no conflicts of interest.

All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

**References**